The major brands in China’s urinalysis market are URIT, DIRUI, AVE, etc. URIT produced China’s first urine analyzer in 1984. And after nearly 40 years’ strenuous cultivation, it pioneered the modular urine analysis workflow using deep learning artificial intelligence (AI) image recognition technology.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Breast Cancer Canada said on Thursday that it has launched a new grant program in collaboration with AstraZeneca Canada and Illumina.

On June 15, 2023, the inaugural meeting of Institute of Bioinformatics of Shanghai Academy of Experimental Medicine (hereinafter referred to as "Institute of Bioinformatics") and Gene Sequencing Bioinformatics Research Summit Forum was held in Intercontinental Hotel in Jing'an, Shanghai. Ltd.

Eli Lilly and Verve Therapeutics on Thursday said they have entered into an exclusive research collaboration to advance a preclinical gene-editing therapy for atherosclerotic cardiovascular disease (ASCVD) into the clinical stage.

MGI Tech, a Shenzhen, China-based firm focused on the development and distribution of sequencing instruments and reagents, on Wednesday announced that it has signed a licensing agreement with Xpress Genomics.

Seegene Inc. (KQ096530), a leading South Korean company which provides a total solution for PCR molecular diagnostics, announced an agreement with Werfen, a worldwide leader in Specialized Diagnostics, to advance discussions on the expansion of its current collaboration for the Spanish and Portuguese marketplaces through Seegene's OneSystem™ Business.

On June 9, a launching ceremony was held for the Stago Medical Device Factory. On the same day, the opening ceremony of DiaSorin’s Baoshan factory was held.

Becton, Dickinson and Company (BD) has globally introduced the new automated instrument, the BD FACSDuet Premium Sample Preparation System, for cellular diagnostic applications.

The National Institutes of Health (NIH) has awarded a $4.6 million contract to Sorrento Therapeutics to develop an in vitro diagnostic testing platform for biodefense, antimicrobial-resistant infections, and emerging infectious diseases, the firm said Tuesday.

Point-of-care testing (POCT), also known as "bedside testing" or "near-patient testing," is a test performed near or at the patient's location that may result in a change in the patient's disposition.

DiaSorin said Tuesday that it has secured CE marking for an immunodiagnostic assay to aid diagnosis of severe conditions including sepsis, septic shock, kidney diseases, and lower respiratory and urinary tract infections, and the firm is launching the assay in Europe.